Coeptis Therapeutics Holdings Inc
For the period ended Jun 30, 2024. Filed Aug 16, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 16, 2024
ZSQR$2.79-17.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended | Six Months Ended | |||
|---|---|---|---|---|
| June 30, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | |
| SALES | ||||
| Consulting services | $– | $– | $– | $– |
| Sales | – | – | – | – |
| Total sales | – | – | – | – |
| Cost of goods | – | – | – | – |
| Gross profit | – | – | – | – |
| COST OF OPERATIONS | ||||
| Research and development expense | 398,817 | 466,629 | 1,175,886 | 581,959 |
| Salary expense | 459,099 | 355,927 | 904,458 | 639,844 |
| Amortization expense | 250,000 | 250,000 | 500,000 | 500,000 |
| Professional services expense | 864,588 | 2,298,224 | 2,045,087 | 7,850,310 |
| Stock based compensation expense | 611,570 | 113,391 | 708,459 | 235,692 |
| General and administrative expenses | 239,028 | 200,513 | 411,595 | 415,831 |
| Selling and marketing expense | 5,000 | 300 | 5,000 | 300 |
| Total cost of operations | 2,828,102 | 3,684,984 | 5,750,485 | 10,223,936 |
| LOSS FROM OPERATIONS | (2,828,102) | (3,684,984) | (5,750,485) | (10,223,936) |
| OTHER INCOME (EXPENSE) | ||||
| Interest expense | (66,056) | (42,636) | (266,561) | (74,053) |
| Other income | 8,063 | – | 94,688 | 35 |
| Change in fair value of derivative liability warrants | (149,250) | 525,000 | (114,375) | (862,500) |
| TOTAL OTHER INCOME (EXPENSE), net | (207,243) | 482,364 | (286,248) | (936,518) |
| LOSS BEFORE INCOME TAXES | (3,035,345) | (3,202,620) | (6,036,733) | (11,160,454) |
| PROVISION FOR INCOME TAXES (BENEFIT) | – | – | – | – |
| NET LOSS | (3,035,345) | (3,202,620) | (6,036,733) | (11,160,454) |
| Net loss attributable to noncontrolling interests | – | – | – | – |
| NET LOSS ATTRIBUTABLE TO COEPTIS THERAPEUTICS HOLDINGS, INC. | $(3,035,345) | $(3,202,620) | $(6,036,733) | $(11,160,454) |
| LOSS PER SHARE | ||||
| Loss per share, basic and fully diluted | $(0.08) | $(0.15) | $(0.17) | $(0.53) |
| Weighted average number of common shares outstanding | 37,569,312 | 21,808,563 | 36,551,418 | 21,080,395 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.